Our past and present findings indicate that the SIK2 inhibitor ARN-3261 enhances sensitivity to both carboplatin and paclitaxel in cultured ovarian cancer cell lines as well as in xenograft models, supporting its potential role in the treatment of primary as well as recurrent ovarian cancer. Here, SIK2 is linked to ovarian carcinoma.